U.S,Ca:18006380796

Contact Us

Biosimilar Monoclonal Antibodies Market Poised to Grow at a CAGR of 42.8% by 2023


Infinium Global Research has added a new report on Biosimilar Monoclonal Antibodies Market. The report presents analysis of global as well as regional markets of biosimilar monoclonal antibodies market over the period of 2016 to 2024. A monoclonal antibody is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. A monoclonal antibody is made so that it binds to only one substance to treat different types of cancer. There are several types of monoclonal antibodies that are being used to treat certain types of cancer. Laboratory production of monoclonal antibodies is produced from clones of only one cell which means that every monoclonal antibody produced by the cell is the same due to which they are called as biosimilar monoclonal antibodies. Each monoclonal antibody recognizes one particular protein. They work in different ways depending on the protein they are targeting, hence different monoclonal antibodies are required to be made to target different types of cancer.

 

The global biosimilar monoclonal antibodies market is driven by the factors such as rising demand for biosimilar drugs owing to their cost effectiveness, patent expiration of biologics, and prevalence of chronic diseases among geriatric population. However, unfavorable government regulations in developed economies and high cost associated with manufacturing process are likely to act as a primary restraining factors affecting the global biosimilar monoclonal antibodies market over the forecast period. Moreover, emerging markets owing to relaxed regulations are expected to provide more opportunities for the manufacturers of biosimilar drugs.

 

Among the geographies, Europe is an important market for biosimilar monoclonal antibodies market globally due to favorable regulatory policies designed by the European Medical Association (EMA) and since Europe was the first region to draft guidelines for approval of biosimilar products. The Asia pacific region accounted for the largest market size while North America biosimilar monoclonal antibodies market is projected to grow at a CAGR of x.xx% over the forecast period. Moreover, the growth matrix presented by Infinium Global Research identifies the key investment markets in the near future, this will not only help the companies to understand the competitive position in the global biosimilar monoclonal antibodies market but also make strategic decisions to capture the most lucrative markets in the near future. The market size is presented in terms of value for the historic year 2016 and estimated for forecast period of 2018-2024.

 

 

Get 15% discount for early purchase of global biosimilar monoclonal antibodies market report by clicking the following link, Use code IGRD15 to request the discount in the given form

 

https://www.infiniumglobalresearch.com/reports/request-discount/72

 

The recent report identified that Europe dominated the global biosimilar monoclonal antibodies market over the last couple of years, while emerging markets of Asia-Pacific and Latin America are anticipated to contribute significantly to the growth in the biosimilar monoclonal antibodies market worldwide.

 

The report segments the global biosimilar monoclonal antibodies market on the basis of Application and Drug Class.

 

Global Biosimilar Monoclonal Antibodies Market by Application

·         Diagnostic Applications

o   MAbs in Biochemical Analysis

§  Pregnancy

§  Cancers

§  Hormonal disorders

§  Infectious diseases

o   MAbs in Diagnostic Imaging

§  Cardiovascular diseases

§  Deep vein thrombosis (DVT)

§  Atherosclerosis

§  Cancers

§  Bacterial infections

·         Therapeutic Applications

o   MAbs as Direct Therapeutic Agents

o   MAbs as Targeting Agents in Therapy

·         Protein Purification

 

Global Biosimilar Monoclonal Antibodies Market by Drug Class

·         Rituximab

·         Infliximab

·         Abciximab

·         Trastuzumab

·         Adalimumab

·         Bevacizumab

 

Companies Profiled in the Report

·          Pfizer, Inc.

·         Novartis AG

·         Reliance Life Sciences

·         Allergan plc